Navigation Links
Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments
Date:4/29/2009

o fees and milestone payments that could amount to as much as $183.0 million, including $33.0 million received to date. HGS is also entitled to single-digit royalties on worldwide sales if Syncria is commercialized.

HGS and Morphotek Agree to Collaborate on Discovery, Development and Commercialization of Therapeutic Antibodies for Oncology and Immunology

In March 2009, HGS and Morphotek, Inc., a subsidiary of Eisai Corporation of North America, entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies in the fields of oncology and immunology that specifically target antigens discovered by HGS. Morphotek will be responsible for validating targets discovered through genomic research provided by HGS, generating and developing all monoclonal antibody candidates using proprietary Morphotek technologies, and conducting early preclinical proof-of-concept studies. HGS and Morphotek will have the right to participate in the development and commercialization of each antibody candidate.

CONFERENCE CALL

HGS management will hold a conference call to discuss this announcement today at 5 PM Eastern time. Investors may listen to the call by dialing 877-591-4959 or 719-325-4901, passcode 2810740, five to 10 minutes before the start of the call. A replay of the conference call will be available within a few hours after the call ends. Investors may listen to the replay by dialing 888-203-1112 or 719-457-0820, confirmation code 2810740. Today's conference call also will be webcast and can be accessed at www.hgsi.com. Investors interested in listening to the live webcast should log on before the conference call begins to download any software required. Both the audio replay and the archive of the conference call webcast will remain available for several days.

ABOUT HUMAN GENOME SCIENCES
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 2015 S&P Capital IQ (MHFI) announced today ... on MabVax Therapeutics Holdings Inc . ... biotechnology company focused on the development of vaccine and ... treatment of cancer. MabVax has discovered a pipeline of ... responses generated by patients who have been immunized against ...
(Date:2/26/2015)... 26, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... company that develops and commercializes proprietary technologies and products ... operational results for the fiscal first quarter ended December ... in Canadian dollars (CAD), unless otherwise stated. ... new business from our existing customers and add to ...
(Date:2/26/2015)... 2015 Protiviti ( www.protiviti.com ), a global ... Governance Portal , designed to increase the efficiency ... tasks across multiple business units and projects. The Governance ... better align their controls with the COSO ( Committee ... In response to client feedback, Protiviti has also included ...
(Date:2/26/2015)... On behalf of biotech client GenScript ... Goldman & Spitzer, P.A. (Wilentz) secured a significant ... Inc. in excess of $10 million. The jury determined ... and that it improperly hired one or more of ... motions for judgment notwithstanding the verdict, a new trial, ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... DALLAS , June 29, 2010 , ... - ReportsandReports Announces it Will Carry the Disease and Therapy,Review: Asthma ... Browse the ... The Asthma Disease ...
... 29 Reportlinker.com announces that a new market research ... , , ... Biologics: Global Market Outlook 2010-2025 - opportunities and challenges in ... , , ...
... VANCOUVER , June 28 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc. ... its Special Meeting of Shareholders will be held on Tuesday, ... at the Company,s corporate office located at Suite 310, 650 West ... shareholders of record of as of May 28, 2010 ...
Cached Biology Technology:Disease and Therapy Review: Asthma Now Available at ReportsandReports 2Disease and Therapy Review: Asthma Now Available at ReportsandReports 3Disease and Therapy Review: Asthma Now Available at ReportsandReports 4Disease and Therapy Review: Asthma Now Available at ReportsandReports 5Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 2Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 3Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 4Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 5Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 6Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 7Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 8Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 9Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 10Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 11Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 12Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 13Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 14Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 15Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 16Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 17Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 18Dragon Pharma announces date of special meeting 2
(Date:2/5/2015)... , 5. Februar 2015 ... spezialisiertes Logistikunternehmen und hat eine neue Marketingkampagne ... Logistikfirma (Clinical Logistics Organization – CLO) der ... Kampagne lautet First , mit Schwerpunkt ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 Logo ...
(Date:2/5/2015)... --NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... on the growing mobile commerce market, announces the launch ... part of its 2015 marketing and branding initiatives for ... consumer website for Wocketwallet.com earlier this month. ... "Our new corporate website naturally showcases our premiere consumer ...
(Date:2/5/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... Online CEO Conference on January 29 th at ... , CEO of NXT-ID will present and host a ... smart wallet and its full suite of biometric technologies. ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3
... -- Time marches on, and thanks to Michigan ... can monitor changes over time more accurately and ... are essential for sustainable management of coupled human ... "Jack" Liu, Rachel Carson Chair in Sustainability at ...
... Human Genome Project ended a decade ago, scientists thought that ... about our genes. But what they really did was open ... of Tel Aviv University,s Cohn Institute for the History and ... of scientific studies concerned with epigenetics, Prof. Jablonka concludes that ...
... addicts for nearly 50 years. Yet we have surprisingly ... New research from the Norwegian Institute of Public Health ... attention of experimental animals. In general, opioids ... intellectual functions such as learning, memory and attention. ...
Cached Biology News:Traumatizing your DNA 2Long-term methadone treatment can affect the brain 2
Human Glypican 2 Biotinylated Affinity Purified PAb...
B2-Microgloulin...
... Molecular Imaging's proprietary Focus™ detector technology, while ... the R4. The microPET Focus 120 ... avaiable PET scanner. Focus scanners also ... scinitallor based PETsystems. The combination of ...
...
Biology Products: